Targeted microbubbles for imaging tumor angiogenesis: Assessment of whole-body biodistribution with dynamic micro-PET in mice

被引:145
|
作者
Willmann, Juergen K. [1 ,2 ]
Cheng, Zhen [1 ,2 ]
Davis, Corrine [3 ]
Lutz, Amelie M. [1 ,2 ]
Schipper, Meike L. [1 ,2 ]
Nielsen, Carsten H. [1 ,2 ]
Gambhir, Sanjiv S. [1 ,2 ,4 ]
机构
[1] Stanford Univ, Sch Med, Mol Imaging Program, Dept Radiol,James H Clark Ctr, Stanford, CA 94305 USA
[2] Stanford Univ, Sch Med, James H Clark Ctr, Bio X Program, Stanford, CA 94305 USA
[3] Stanford Univ, Sch Med, James H Clark Ctr, Dept Comparat Med, Stanford, CA 94305 USA
[4] Stanford Univ, Sch Med, James H Clark Ctr, Dept Bioengn, Stanford, CA 94305 USA
关键词
D O I
10.1148/radiol.2491072050
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To evaluate in vivo whole-body biodistribution of microbubbles (MBs) targeted to tumor angiogenesis-related vascular endothelial growth factor (VEGF) receptor 2 (VEGFR2) by using dynamic micro-positron emission tomography (PET) in living mice. Materials and Methods: Animal protocols were approved by the Institutional Administrative Panel on Laboratory Animal Care. Lipid-shell perfluorocarbon-filled MBs, targeted to VEGFR2 via anti-VEGFR2 antibodies, were radiolabeled by conjugating the radiofluorination agent N-succinimidyl-4-[F-18]fluorobenzoate (SFB) to the anti-VEGFR2 antibodies. These MBs were then injected intravenously into nude mice (n = 4) bearing angiosarcomas, and the whole-body biodistribution of these probes was assessed for 60 minutes by using dynamic micro-PET. Results were compared with ex vivo gamma counting (n = 6) and immunofluorescence staining (n = 6). Control studies in angiosarcoma-bearing mice were performed with injection of the radiolabeled antibodies alone (n = 3) or free SFB (n = 3). A mixed-effects regression of MB accumulation on fixed effects of time and tissue type (tumor or muscle) and random effect of animal was performed. Results: VEGFR2-targeted MBs rapidly cleared from the blood circulation (50% blood clearance after approximately 3.5 minutes) and accumulated in the liver (mean, 33.4% injected dose [ID]/g +/- 13.7 [standard deviation] at 60 minutes) and spleen (mean, 9.3% ID/g +/- 6.5 at 60 minutes) on the basis of micro-PET imaging. These findings were confirmed with ex vivo gamma counting. Uptake of targeted MBs was significantly higher (P < .0001) in tumor than in adjacent skeletal muscle tissue. Immunofluorescence staining demonstrated accumulation of the targeted MBs within hepatic Kupffer cells and splenic macrophages. Biodistribution of the radiolabeled antibodies and free SFB differed from the distribution of the targeted MBs. Conclusion: Dynamic micro-PET allows assessment of in vivo biodistribution of VEGFR2-targeted MBs. (C) RSNA, 2008.
引用
收藏
页码:212 / 219
页数:8
相关论文
共 50 条
  • [41] Direct comparison of radiation dosimetry of six PET tracers using human whole-body imaging and murine biodistribution studies
    Muneyuki Sakata
    Keiichi Oda
    Jun Toyohara
    Kenji Ishii
    Tadashi Nariai
    Kiichi Ishiwata
    Annals of Nuclear Medicine, 2013, 27 : 285 - 296
  • [42] Direct comparison of radiation dosimetry of six PET tracers using human whole-body imaging and murine biodistribution studies
    Sakata, Muneyuki
    Oda, Keiichi
    Toyohara, Jun
    Ishii, Kenji
    Nariai, Tadashi
    Ishiwata, Kiichi
    ANNALS OF NUCLEAR MEDICINE, 2013, 27 (03) : 285 - 296
  • [43] Can Dynamic Whole-Body FDG PET Imaging Differentiate between Malignant and Inflammatory Lesions?
    Skawran, Stephan
    Messerli, Michael
    Kotasidis, Fotis
    Trinckauf, Josephine
    Weyermann, Corina
    Kudura, Ken
    Ferraro, Daniela A.
    Pitteloud, Janique
    Treyer, Valerie
    Maurer, Alexander
    Huellner, Martin W.
    Burger, Irene A.
    LIFE-BASEL, 2022, 12 (09):
  • [44] Positron Emission Tomography (PET) Imaging with [11C]-Labeled Erlotinib: A Micro-PET Study on Mice with Lung Tumor Xenografts
    Memon, Ashfaque A.
    Jakobsen, Steen
    Dagnaes-Hansen, Frederik
    Sorensen, Boe S.
    Keiding, Susanne
    Nexo, Ebba
    CANCER RESEARCH, 2009, 69 (03) : 873 - 878
  • [45] The optimization of image quality in dynamic whole-body PET imaging using phantom and clinical data
    Sagara, Hiroaki
    Inoue, Kazumasa
    Ohsawa, Amon
    Muramatsu, Yoshihisa
    Fujii, Hirohumi
    Inaki, Anri
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [46] The role of whole-body FDG-PET in preoperative assessment of tumor staging in oral cancers
    Yoshiki Nakasone
    Tomio Inoue
    Noboru Oriuchi
    Kazuo Takeuchi
    Akihide Negishi
    Keigo Endo
    Kenji Mogi
    Annals of Nuclear Medicine, 2001, 15 : 505 - 512
  • [47] The role of whole-body FDG-PET in preoperative assessment of tumor staging in oral cancers
    Nakasone, Y
    Inoue, T
    Oriuchi, N
    Takeuchi, K
    Negishi, A
    Endo, K
    Mogi, K
    ANNALS OF NUCLEAR MEDICINE, 2001, 15 (06) : 505 - 512
  • [48] 3D BIODISTRIBUTION OF WHOLE-BODY AAV-MEDIATED GENE EXPRESSION IN MICE USING CRYOVIZ™ IMAGING
    Gargesha, M.
    Caligiuri, S.
    Scott, B.
    Kenny, P. J.
    Roy, D.
    CYTOTHERAPY, 2021, 23 (05) : S158 - S158
  • [49] qPSMA: First semi-automatic tool for whole-body tumor burden assessment in prostate cancer PET imaging and preliminary evaluation for PSMA-targeted radioligand therapy
    Gafita, A.
    Bieth, M.
    Kroenke, M.
    Schwaiger, S.
    Heck, M.
    Tauber, R.
    D'Alessandria, C.
    Schwaiger, M.
    Weber, W.
    Eiber, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S524 - S524
  • [50] Whole-Body Biodistribution, Dosimetry, and Metabolite Correction of [11C]Palmitate: A PET Tracer for Imaging of Fatty Acid Metabolism
    Christensen, Nana L.
    Jakobsen, Steen
    Schacht, Anna C.
    Munk, Ole L.
    Alstrup, Aage K. O.
    Tolbod, Lars P.
    Harms, Hendrik J.
    Nielsen, Soren
    Gormsen, Lars C.
    MOLECULAR IMAGING, 2017, 16